



## Schelin Catheter® - new study confirms efficiency and ease of use

**In a newly published study [1] in The Canadian Journal of Urology™, Transurethral Intraprostatic Anesthesia with Schelin Catheter®, effectively controlled operative and postoperative pain related to water vapor therapy.**

The standard analgesic approach for water vapor therapy is transrectal periprostatic block (PNB) or systemic sedation anesthesia. PNB is uncomfortable and holds a risk of infection. Sedation poses safety risks and presence of anesthesiology team.

Use of transurethral intraprostatic anesthesia (TUIA) using Schelin Catheter® provides a non-invasive, efficient technique for out-patient, office-based procedures.

In the article "Use of the Schelin Catheter® for transurethral intraprostatic anesthesia prior to Rezūm treatment" the research team, with urologists from Canada, Italy, and USA, evaluated the efficacy of TUIA via Schelin Catheter® on ten consecutive patients, by monitoring pain before, during and after the water vapor therapy.

The authors reported that Schelin Catheter® was simple to prepare and manipulate, and that the administration of anesthetics resulted in effective pain control. Their experience when using Schelin Catheter®, is that is more efficient compared to PNB, general anesthesia and intravenous sedation. "Given the reduced need for equipment, set-up, and training compared to other analgesic methods, time is greatly optimized by using the Schelin Catheter®."

Dr Kevin Zorn, former Associate Professor of Urology at University of Montreal Hospital Center and University of Chicago, current founder, and director of BPH Canada Prostate Surgery Institute "-While most urological procedures of the prostate require general anesthesia or transrectal PNB (along with their associated risks), these preoperative measures require expensive equipment and pose the risk of complications that can negatively affect patient outcomes and experience. Given our current results, TUIA via the novel Schelin Catheter®, is demonstrably an effective, efficient, non-invasive analgesic method that reduces cost and training, bridging the gap between preoperative care and emerging BPH office-based MISTs."

"We are encouraged to see how efficient and easy to use our Schelin Catheter® is, and we look forward to continuing working with urologist across the globe in our mission to improve patient outcome" says Anders Kristensson, CEO of ProstaLund.

1. <https://canjurol.com/how-i-do-it>
2. MIST – Minimally Invasive Surgery Techniques



PRESS RELEASE  
27 February 2024 14:00:00 CET

**For further information, please contact:**

---

Anders Kristensson, CEO  
Tel. +46 (0) 769 42 12 16  
Email: anders.kristensson@prostalund.com

**About ProstaLund**

---

ProstaLund AB is a Swedish medical technology company and a leading developer and manufacturer of innovative urological devices and treatments. The company's lead product, CoreTherm, is a patented Thermotherapy treatment method for Benign Prostatic Hyperplasia (BPH) which can be tailored to suit the needs of each individual patient. CoreTherm is used today in hospitals and clinics in Sweden and worldwide. ProstaLund is listed on the Nasdaq First North Growth Market.

**Certified Adviser:**

Västra Hamnen Corporate Finance AB  
Phone: +46 40 200 250  
E-mail: ca@vhcorp.se

**Attachments**

---

Schelin Catheter® - new study confirms efficiency and ease of use